Sign In / Join

close

Treatment Advances

Our Treatment Advances articles cover treatment option updates, new combinations of treatments, FDA approval news, and more.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

The Latest in Pediatric AML Research and Innovations

January 16, 2025

Explore breakthroughs in pediatric AML, from cardiac care to therapies, highlighted at the ASH annual conference.

Updates in Treatment Options for TP53-Mutant AML and MDS

December 19, 2024

Learn about cellular therapies recommended for people who have TP53-mutant acute myeloid leukemia and myelodysplastic syndromes.

FDA Approves New Treatment for R/R Acute Leukemia with KMT2A Translocation: Revumenib

November 19, 2024

Learn about revumenib, a newly FDA-approved treatment for relapsed/refractory acute leukemias with the KMT2A gene translocation.

AML: Donor Age, Not Just a Number

October 24, 2024

Discover key insights into AML donor selection, HLA mismatch, and the role of donor age in improving transplant outcomes and reducing complications.

Venetoclax + Decitabine Improve Senior AML Patients’ Chances of Receiving a Transplant

October 22, 2024

Learn how venetoclax and decitabine helped a higher percentage of senior AML patients achieve a complete reduction in AML signs/symptoms and reach transplant.

NPM1 Mutation in AML: Prognosis, Testing, & Treatments

October 04, 2024

What is the NPM1 mutation in acute myeloid leukemia (AML)? How common is it and how is it treated? Learn answers to these questions!

New Trial Required for Iomab-B FDA Approval

September 17, 2024

Learn why the FDA requested another trial for Iomab-B and what this means for AML patients seeking new treatment options.

FDA Grants Priority Review for Revumenib to Treat Relapsed or Refractory AML

September 06, 2024

Revumenib gains FDA Priority Review for treating relapsed KMT2A-rearranged leukemia, with a decision expected by September 26, 2024.

Advances in Vyxeos Therapy Research with Jeffrey Lancet, MD

August 06, 2024

Dr. Lancet shares the ongoing research at Moffitt Cancer Center for patients with acute myeloid leukemia.

New FDA-Designated Cell Therapy for AML, ALL, and MDS

July 15, 2024

TCR-T Therapies TSC-100 and TSC-101 were given FDA Designation in AML, ALL, and MDS.

Treatment Advances

Recent Articles

The Latest in Pediatric AML Research and Innovations

Updates in Treatment Options for TP53-Mutant AML and MDS

FDA Approves New Treatment for R/R Acute Leukemia with KMT2A Translocation: Revumenib

AML: Donor Age, Not Just a Number

Venetoclax + Decitabine Improve Senior AML Patients’ Chances of Receiving a Transplant

NPM1 Mutation in AML: Prognosis, Testing, & Treatments

New Trial Required for Iomab-B FDA Approval

FDA Grants Priority Review for Revumenib to Treat Relapsed or Refractory AML

Advances in Vyxeos Therapy Research with Jeffrey Lancet, MD

New FDA-Designated Cell Therapy for AML, ALL, and MDS

Trending Articles

Venetoclax Plus 7+3 Chemotherapy: A Promising Induction Therapy for Newly Diagnosed AML

Understanding TP53 Mutations in AML and MDS: Expert Insights from ASH 2024

Former NHL Player Kelly Chase Shares an Update on His AML Treatment

Breaking Barriers in AML Care: Addressing Survival Disparities in Young Adults

Updates in Treatment Options for TP53-Mutant AML and MDS

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Follow Us

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info

Treatment Advances

Recent Articles

The Latest in Pediatric AML Research and Innovations

Updates in Treatment Options for TP53-Mutant AML and MDS

FDA Approves New Treatment for R/R Acute Leukemia with KMT2A Translocation: Revumenib

AML: Donor Age, Not Just a Number

Venetoclax + Decitabine Improve Senior AML Patients’ Chances of Receiving a Transplant

NPM1 Mutation in AML: Prognosis, Testing, & Treatments

New Trial Required for Iomab-B FDA Approval

FDA Grants Priority Review for Revumenib to Treat Relapsed or Refractory AML

Advances in Vyxeos Therapy Research with Jeffrey Lancet, MD

New FDA-Designated Cell Therapy for AML, ALL, and MDS

Trending Articles

Venetoclax Plus 7+3 Chemotherapy: A Promising Induction Therapy for Newly Diagnosed AML

Understanding TP53 Mutations in AML and MDS: Expert Insights from ASH 2024

Former NHL Player Kelly Chase Shares an Update on His AML Treatment

Breaking Barriers in AML Care: Addressing Survival Disparities in Young Adults

Updates in Treatment Options for TP53-Mutant AML and MDS

Sign Up for Exclusive Acute Myeloid Leukemia Updates & Resources.

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Follow Us

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info